HGS Lymphostat-B Is 1 Of 7 Agents Selected For FDA’s Pilot 2 CMA Program
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA has selected Human Genome Sciences’ lupus biologic Lymphostat-B for the continuous marketing application (CMA) Pilot 2 program, HGS announced March 4.